LITHUM-ASSOCIATED



HYPERPARATHYROIDISM

ACASE REPORT

M. Marcelino¹, J. Silva¹, F. Lopes¹, L. Lopes¹, L. Salgado², C.Lopes³, J. Jácome de Castro¹

Endocrinology¹, Nuclear Medicine² and Surgery³ Departments

Armed Forces University Hospital, Lisbon

INTRODUCTION: Lithium therapy is commonly used in bipolar disorder treatment. Alongside the increasing prevalence of

goiter and hypothyroidism, the sustaining use of lithium therapy is associated with several metabolic disorders, such as

hypercalcemia and hyperparathyroidism (HPT).

CASE REPORT:

A 64-year-old woman with history of bipolar disorder

treated with lithium for several years was referred to our


department for evaluation of recurrent hypercalcemia and

asymptomatic multinodular goiter (MNG).

Euthyroid MNG (benign fine needle biopsy) and a lithiumassociated Hyperparathyroidism (blood calcium 10.6 mg/

dl (8,4–10.2); phosphorus 2,06 mg/dl (2,0-4,0) PTH

256pg/dl (15-60)) were diagnosed. SestaMIBI scan was



A total thyroidectomy and a left lower parathyroidectomy

were performed. Histology confirmed a PTA with

negative. A bone mineral densitometry showed reduced T-score in forearm (-2.0).

As lithium therapy was essential and could not be discontinued, we started bisphosphonate therapy (alendronate 70mg/week) and conservative management with regular follow-up was planned.


After 1 year of follow-up she showed a severe deterioration of the HPT with increasing calcium levels (12,8mg/dl). A new SestaMIBI scan suggested a left lower parathyroid adenoma (PTA) and was referred to surgery.

13x12x8mm and a follicular hyperplasia of the thyroid gland, with multinodular goiter. After surgery, the calcium levels normalized and PTH levels decreased. She starts treatment with levothyroxine and maintained lithium

therapy.

SestaMIBI (Sep12)

During 1 year, its calcium levels sustain normal, but PTH levels were mildly increased. She performed another SestaMIBI scan that was negative. She maintains a conservative management with regular follow up in our department.





DISCUSSION: It is still unclear whether lithium-associated HPT causes four-gland hyperplasia or promotes the growth of

pre-existing parathyroid adenomas (PTA). This leads to a discussion about what should be the best surgical approach. A

four-gland exploration is frequently necessary, but excision of simple adenomas may be a valid option. Patients under

lithium therapy should be closely monitored to potential HPT, attempting early diagnosis and avoiding associated

comorbidities.

REFERENCES:

- BROWN EM: Lithium induces abnormal calcium-regulated PTH release in dispersed bovine parathyroid cells. J Clin Endocrinol Metab 1981; 52: 1046-8
- RICCARDI D, GAMBA G: The many roles of the calcium-sensing receptor in health and disease. Arch Med Res 1999; 30: 436-48
- SZALAT A, MAZEH H, FREUND HR: Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur J Endocrinol 2009; 160: 317-23
- SAUNDERS BD, SAUNDERS EF, GAUGER PG: Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg 2009; 33: 2314-23
- MARTI JL, YANG CS, CARLING T, et al.: Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism. Ann Surg Oncol 2012; 19: 3465-71
- JARHULT J, ANDER S, ASKING B, et al.: Long-term results of surgery for lithium-associated hyperparathyroidism. Br J Surg 2010; 97: 1680-5

CONTACTS:

Serviço de Endocrinologia, Diabetes e Metabolismo, HFAR:endoc.hmp@sapo.pt Mafalda Marcelino: marcelino.mafalda@gmail.com